title: Interventions in progressive supranuclear palsy.
abstract: Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathy (Richardson's syndrome). Currently, no effective symptomatic or neuroprotective treatment is available for PSP. Current medical have a limited role in PSP. Novel experimental treatments include davunetide or tideglusib, both inhibitors of glycogen synthase kinase-3 (GSK-3) that failed to improve the clinical outcome of PSP patients in two recent studies. Future interventions aiming at tau dysfunction and passive or active immunization are ongoing or underway.
authors.affiliation: Movement Disorders Clinic, Second Dept. of Neurology, Attikon Hospital, University of Athens, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Koros
authors.affiliation: Movement Disorders Clinic, Second Dept. of Neurology, Attikon Hospital, University of Athens, Greece; Dept. of Movement Disorders, Hygeia Hospital, Athens, Greece; Neurology Clinic, Philipps University, Marburg, Germany. Electronic address: mariastamelou@gmail.com.
authors.forename: Maria
authors.initials: M
authors.lastname: Stamelou
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors*; D006801:Humans; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis* / Q000188:drug therapy*; D013830:Thiadiazoles / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D013830:Thiadiazoles; D038362:Glycogen Synthase Kinase 3; C520571:tideglusib
keywords: Davunetide; Glycogen synthase kinase-3 inhibitors; Immunization; Progressive supranuclear palsy; Richardson's syndrome; Tideglusib; Treatment